SuanFarma-Header SuanFarma-Header


Find Novel Drugs for Genetic Disease under Development in UNITED KINGDOM


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Cell-penetrating peptides conjugates

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 09, 2020


            PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical need.